Bio-IT World | The World Health Organization estimates that by 2020, there will be 16 million new cancer cases every year, and there is a continual need for novel therapies that will command premium pricing. In addition, as new medicines prolong life, some current short-term agents could see extended usage, thereby generating additional sales. These forces are driving the expansion of the global oncology market. 

Despite the wealth of potential targets, current drugs address only a handful of the best-characterized oncogenesis pathways, but the number of targets is growing exponentially. While not all of these targets will work, several have the potential to improve efficacy for many tumor types, and contribute significantly to the oncology market over the next five years. Read more.